<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Children with severe <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> requiring mechanical ventilation may become refractory to conventional therapy </plain></SENT>
<SENT sid="1" pm="."><plain>In these <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> patients, <z:chebi fb="0" ids="6015">isoflurane</z:chebi> is an inhaled <z:chebi fb="0" ids="38867">anesthetic agent</z:chebi> available in some centers to treat <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that <z:chebi fb="0" ids="6015">isoflurane</z:chebi> is safe and would lead to improved gas exchange in children with life-threatening <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> refractory to conventional therapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A retrospective review was conducted and included mechanically ventilated children treated with <z:chebi fb="0" ids="6015">isoflurane</z:chebi> in a quaternary pediatric ICU for life-threatening <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e>, from 1993 to 2007 </plain></SENT>
<SENT sid="4" pm="."><plain>Demographic, blood gas, ventilator, and outcome data were collected </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Thirty-one patients, with a mean age of 9.5 years (range 0.4-23 years) were treated with <z:chebi fb="0" ids="6015">isoflurane</z:chebi>, from 1993 to 2007 </plain></SENT>
<SENT sid="6" pm="."><plain>Mean time to initiation of <z:chebi fb="0" ids="6015">isoflurane</z:chebi> after intubation was 13 hours (0-120 h), and the mean maximum <z:chebi fb="0" ids="6015">isoflurane</z:chebi> dose was 1.1% (0.3-2.5%) </plain></SENT>
<SENT sid="7" pm="."><plain>Mean duration of <z:chebi fb="0" ids="6015">isoflurane</z:chebi> administration was 54.5 hours (range 1-181 h), with a total mean duration of mechanical ventilation of 252 hours (range 16-1,444 h) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6015">Isoflurane</z:chebi> led to significant improvement in pH and P(<z:chebi fb="0" ids="16526">CO(2)</z:chebi>) within 4 hours of initiation (P â‰¤ .001) </plain></SENT>
<SENT sid="9" pm="."><plain>Complications during <z:chebi fb="0" ids="6015">isoflurane</z:chebi> administration included <z:hpo ids='HP_0002615'>hypotension</z:hpo> requiring vasoactive infusions in 24 (77%), <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in 3 (10%), neurologic side effects in 3 (10%), and <z:hpo ids='HP_0002107'>pneumothorax</z:hpo> in 1 (3%) patient </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6015">Isoflurane</z:chebi> led to improvement in pH and P(<z:chebi fb="0" ids="16526">CO(2)</z:chebi>) within 4 hours in this series of mechanically ventilated patients with life-threatening <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The majority of patients in this series developed <z:hpo ids='HP_0002615'>hypotension</z:hpo>, but there was a low incidence of other side effects related to <z:chebi fb="0" ids="6015">isoflurane</z:chebi> administration </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="6015">Isoflurane</z:chebi> appears to be an effective therapy in patients with life-threatening <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> refractory to conventional therapy </plain></SENT>
<SENT sid="13" pm="."><plain>However, further investigation is warranted, given the uncertain overall impact of <z:chebi fb="0" ids="6015">isoflurane</z:chebi> in this context </plain></SENT>
</text></document>